Why I believe investing in these FTSE 100 dividend stocks could make you a millionaire retiree

Royston Wild discusses two dynamic dividend stocks from the FTSE 100 (INDEXFTSE: UKX) that could make you richer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Even though Big Pharma has continued to be racked with the impact of colossal patent expirations, investors for the large part seem to be pretty unconcerned.

Take AstraZeneca (LSE: AZN), for example. Its share price has ballooned by more than 80% over the past five years even as the loss of exclusivity on revenue drivers like Crestor has pounded the bottom line.

Quite why the market remains upbeat isn’t a secret. Sure, a return to significant earnings growth may not have been achieved as early as many had been expecting. But the hard yards that the FTSE 100 firm has been putting in on the R&D front is finally starting to pay off.

Should you invest £1,000 in Royal Mail Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Royal Mail Group made the list?

See the 6 stocks

The raft of product approvals over the past half a decade helped the sale of new medicines like Lynparza and Fasenra barge through the $1bn barrier in the first half of 2018. Even though the business has endured some development setbacks in recent years, the strength of its lab teams has still laid the groundwork for sales to rip higher once more.

Profits set to rebound

The rapid progression of AstraZeneca’s recently-launched products, and the encouraging progress seen across its bulging pipeline, clearly give plenty of reason to expect profits to explode sooner rather than later. The emphasis the firm’s putting on emerging markets gives me further grounds for optimism too.

Between January and June, sales to these developing regions rose 14% year-on-year, underpinned by exceptional medicines demand in China where AstraZeneca’s revenues leapt 33%. Sales were helped by the launch of lung cancer battler Tagrisso too, a product which drove total oncology product sales in the Chinese marketplace 57% higher from the same 2017 period.

City analysts expect the company to burst back into growth with a 12% rise in 2019. They may also be expecting dividends to remain frozen at 280 US cents per share through to then — a figure that yields a chubby, inflation-busting 3.7%, incidentally — but I’m confident that having turned the corner, dividends should follow profits higher again.

At current prices, AstraZeneca sports a forward P/E ratio of 22.5 times. Heady on paper, sure, but a figure that I still consider a snip given the rate at which the firm’s new medicines are flying off the shelves.

Testing titan

Intertek Group (LSE: ITRK) is another Footsie firm I believe contains millionaire-maker investment potential.

The inspection and product testing giant has a terrific record of lifting dividends and City analysts are not expecting the trend to end any time soon. Last year’s 71.3p per share payout is predicted to rise to 96p in 2018 and to 106.2p in the following 12-month period.

Subsequent yields of 2.1% and 2.4% for these years may not be anything to write home about. However, Intertek’s bright growth outlook (the City is anticipating further annual profits improvements of 1% this year and 9% next year), assisted by its insatiable appetite for acquisitions, mean that dividends should keep ripping higher for some time to come.

And this makes it one of the hottest income stocks on the FTSE 100, in my opinion. I’d happily buy Intertek alongside AstraZeneca despite its similarly-high paper valuation, a forward P/E multiple of 22.9 times, as the possibility of creating a million-dollar portfolio — along with some other choice stocks from the Footsie — with both or either is too good to miss.

Should you buy Royal Mail Group shares today?

Before you decide, please take a moment to review this first.

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and Intertek. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Cheaper by a third, is Apple stock now a bargain?

Apple stock has fallen steeply of late. This writer would happily invest in the iPhone maker at the right price.…

Read more »

Investing Articles

Up 60%! See the stunning easyJet share price forecast for 2025

Harvey Jones is impressed to see just how high forecasters expect the easyJet share price to fly over the next…

Read more »

Investing Articles

The BP share price hits a 3-year low. Time to buy?

The BP share price has been trading at levels last seen three years ago, with a 7%+ dividend yield to…

Read more »

Investing Articles

Last week, Rolls-Royce shares were the most popular on this investor platform. But there’s a catch!

Those using the Hargreaves Lansdown website bought more Rolls-Royce shares than any other UK stock last week. But this isn’t…

Read more »

Investing Articles

Here’s how to start investing with £500 as the stock market tumbles

Christopher Ruane reckons a rocky stock market could throw up some bargains, potentially making it a good moment to start…

Read more »

Investing Articles

Down 44% this year, could the Aston Martin share price bounce back?

The Aston Martin share price is in pennies and barely a 10th of what it was five years ago. Could…

Read more »

Young female analyst working at her desk in the office
Dividend Shares

A 9.28% dividend yield? Here’s the forecast for HSBC in 2025 and beyond

Mark Hartley considers the long-term prospects of the UK's largest bank, examining the reasons behind its surging dividend yield and…

Read more »

Investing Articles

A rally could be coming for the UK stock market! Here’s how I aim to profit

Mark Hartley considers a strategy to profit from a potential UK market rally. Which stocks are best-positioned to sidestep the…

Read more »